Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis
Condition(s) studied
Investigational drug(s) / intervention(s)
Bifidobacterium breve: Oral Bifidobacterium breve supplementation, 4.5 × 10\^6 CFU daily for 6 months
Lifestyle Education: A standardized education session delivered at baseline on diet optimization, appropriate exercise, and avoidance of unnecessary antibiotic use.
Study summary
Researchers hypothesized that Bifidobacterium breve Supplement could reduce the progression rate of idiopathic scoliosis in children and potentially prevent the occurrence of new cases of scoliosis.
Eligibility
Primary outcome measure(s)
- Change in Major Cobb Angle — Baseline and every 6 months up to 24 months
Major curve magnitude will be measured on standing full-spine radiographs using the standard Cobb method. - Change in Angle of Trunk Rotation (ATR) — Baseline and every 6 months up to 24 months
Trunk asymmetry will be assessed using a scoliometer to measure angle of trunk rotation.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| The Second Affiliated Hospital of Wenzhou Medical University, Zhejiang, Zhejiang 325000 | Wenzhou | Zhejiang |
More Second Affiliated Hospital of Wenzhou Medical University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07466511 on ClinicalTrials.gov ↗ ← All trials in China